Physician profile
Christopher Barnes
NPI 1982018933
$478.07
in general payments reported to CMS, 2019-2025
16 companies · $56.77 in 2025
The $56.77 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2021: $11.30 · 2022: $34.81 · 2024: $49.84 · 2025: $56.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $42.59 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.12 | 2019 | |
| Amarin Pharma, INC. | $42.01 | 2019 | |
| Medtronic, INC. | $41.07 | 2021-2024 | Minimed 780g |
| Lilly USA, LLC | $38.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.99 | 2019 | |
| Amgen INC. | $37.02 | 2019 | |
| Novo Nordisk INC | $36.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $30.07 | 2019 | |
| Merck Sharp & Dohme LLC | $27.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.50 | 2019 | |
| Abbott Laboratories | $20.07 | 2024 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $16.34 | 2019 | |
| Dexcom, INC. | $14.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $14.18 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.